AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
Key facts
- Where
- Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, and Shanghai, ChinaSee the 8 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07382375, who can take part
Where in China
- Beijing Anzhen HospitalBeijing, ChinaContact: Si-chong Qian, MDNo longer taking part
- Changzhou First People HospitalChangzhou, ChinaContact: Chao Ma, MDNo longer taking part
- West China Hospital of Sichuan UniversityChengdu, ChinaContact: Hong-hua YUE, MDNo longer taking part
- Fujian Medical University Union HospitalFuzhou, ChinaContact: Dong-dong Wu, MDNo longer taking part
- The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaContact: Ying-yuan ZhangNo longer taking part
- Nanchang University Second HospitalNanchang, ChinaContact: Ji-sheng Zhong, MDNo longer taking part
- The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Sheng ZhaoNo longer taking part
- Shanghai East HospitalShanghai, ChinaContact: Guo-liang FanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nanjing Medical University
- Trial code
- NCT07382375
- Record updated
- 2 February 2026
- Original description
Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. This study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a "subtyping-target-treatment" closed loop for emergency needs. Using a prospective multicenter RCT, 300 patients are randomly divided into two groups: the experimental group receives subtyping-based precision therapy, while the control group uses empirical strategies (treatment of physician's choice). It observes 7-day postoperative SOFA score, SIRS and other prognostic indicators to provide evidence-based support for precision treatment.Read full original descriptionShow less
AI-assisted Immunoinflammatory Subtyping-Directed Precision Treatment in Acute Aortic Dissection: A Multicenter RCT-based Exploration
Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. This study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a "subtyping-target-treatment" closed loop for emergency needs. Using a prospective multicenter RCT, 300 patients are randomly divided into two groups: the experimental group receives subtyping-based precision therapy, while the control group uses empirical strategies (treatment of physician's choice). It observes 7-day postoperative SOFA score, SIRS and other prognostic indicators to provide evidence-based support for precision treatment.
Inclusion: Confirmed diagnosis of acute aortic dissection by contrast-enhanced Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA); Planned emergency surgical treatment (including open surgery and endovascular repair); Aged 18-80 years old, regardless of gender; Time from onset to hospital admission ≤ 72 hours; Signed informed consent form by the patient or their authorized agent, with willingness to cooperate with the follow-up of the study.
Exclusion: Long-term use of immunosuppressants or glucocorticoids before surgery (continuous use for ≥ 2 weeks); Complicated with underlying diseases that affect immunoinflammatory status, such as severe infections (e.g., sepsis, infective endocarditis), autoimmune diseases, malignant tumors, chronic liver diseases, and chronic kidney diseases (uremic stage); Patients with mental disorders or cognitive dysfunction who cannot cooperate with the study; Pregnant or lactating women.